CFRX Insider Trading Activity and SEC Form 4 Filings
CFRX insider trading summary
No open-market insider purchases or sales of CONTRAFECT Corp (CFRX) have been reported on SEC Form 4 in the past 12 months.
Latest CFRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 13, 2019 | Cary Sucoff | Director | Buy | $20K (50,000 @ $0.39) |
| Dec 13, 2019 | David N. Low | Director | Buy | $129K (300,000 @ $0.43) |
| Dec 13, 2019 | Michael Messinger | Chief Financial Officer | Buy | $2K (5,000 @ $0.37) |
| Dec 4, 2018 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% Owner | Sell | $1.2M (600,000 @ $2.04) |
| Dec 4, 2018 | Fosun Industrial Co., Ltd | 10% Owner | Sell | $1.2M (600,000 @ $2.04) |
| Jul 25, 2017 | Cary Sucoff | Director | Buy | $15K (12,000 @ $1.24) |
| Jul 25, 2017 | Steven C Gilman | CEO | Buy | $992 (800 @ $1.24) |
| Jul 25, 2017 | Sol J Barer | Director | Buy | $50K (40,000 @ $1.24) |
| Jul 25, 2017 | Michael J. Otto | Director | Buy | $10K (8,000 @ $1.24) |
| Jul 25, 2017 | Michael Messinger | SVP Finance | Buy | $992 (800 @ $1.24) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.